Prevention of Recurrent Large or Hemorrhagic Ovarian Cysts

Key Clinical Context

The U.S. Medical Eligibility Criteria recognizes that women on anticoagulant therapy face increased risk for hemorrhagic ovarian cysts, and hormonal contraceptive methods can provide benefit in preventing these complications, with the Centers for Disease Control and Prevention recommending careful assessment of thrombotic risk against bleeding complications 1, 2
When contraceptives are used therapeutically rather than solely for pregnancy prevention, the risk-benefit calculation should be assessed individually, particularly weighing thrombotic risk against bleeding complications, according to the U.S. Medical Eligibility Criteria 1, 2

Document cyst characteristics: size, unilateral vs bilateral, simple vs complex, presence of hemorrhage, as recommended by Praxis Medical Insights 3
Identify risk factors: anticoagulation therapy, ovulation induction history, previous cyst episodes, with the U.S. Medical Eligibility Criteria emphasizing the importance of assessing these factors 1, 2

Initiate combined hormonal contraceptives for prevention if medically eligible per U.S. MEC criteria, particularly in anticoagulated patients where hemorrhagic cysts pose significant morbidity risk, with the Centers for Disease Control and Prevention recommending this approach 1, 2
Use nonsteroidal anti-inflammatory drugs (NSAIDs) for 5-7 days for symptomatic relief if bleeding or pain occurs, as recommended by the Centers for Disease Control and Prevention 4, 3

Do not overlook contraindications - assess thrombotic risk factors before initiating combined hormonal contraceptives, particularly in women with history of deep vein thrombosis/pulmonary embolism, with the U.S. Medical Eligibility Criteria emphasizing the importance of careful assessment 1, 2